Seema B. Singhal

Hematology

675 N St Clair St Ste 21-100
Galter Pavilion
Chicago, IL 60611

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Cardiovascular Adverse Events Following Bispecific T-Cell Redirecting Antibody Therapy.

Cardiovascular Adverse Events Following Bispecific T-Cell Redirecting Antibody Therapy.

Journal: JACC. CardioOncology

Published: August 18, 2025

Variance in development of early and late cardiotoxicities in patients with lymphoma and myeloma receiving CAR T-cell therapies.

Variance in development of early and late cardiotoxicities in patients with lymphoma and myeloma receiving CAR T-cell therapies.

Journal: Leukemia & lymphoma

Published: January 08, 2025

Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States.

Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States.

Journal: JCO oncology practice

Published: May 30, 2020

NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020.

NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: October 08, 2019

A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.

A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.

Journal: Blood advances

Published: May 23, 2019

Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma.

Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma.

Journal: Blood cancer journal

Published: April 20, 2018

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: January 04, 2018

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: February 12, 2017

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 10, 2016

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.

Journal: Lancet (London, England)

Published: January 19, 2016

A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.

A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.

Journal: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Published: November 21, 2015

Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: November 11, 2015

Showing 1-12 of 26

Last Updated: 09/26/2026